Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome

Pharmacology

Volumn 91, Issue 5-6, 2013, Pages 259-266

  Yuan, Hang ^a   Liu, Nian ^a   Sun, Guang Dong ^a   Jia, Ye ^a   Luo, Ping ^a   Miao, Li Ning ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Idiopathic membranous nephropathy; Nephrotic syndrome; Prolonged treatment; Tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIPID; PREDNISONE; PROTEIN; SERUM ALBUMIN; TACROLIMUS; CHOLESTEROL; CREATININE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IDIOPATHIC DISEASE; LIPID BLOOD LEVEL; LONG TERM CARE; LOW DRUG DOSE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RECURRENCE RISK; RECURRENT DISEASE; REMISSION; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC PATIENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; IDIOPATHIC MEMBRANOUS NEPHROPATHY; KIDNEY BIOPSY; MIDDLE AGED; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84877661030     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000348570     Document Type: Article

References (22)

1. Tryggvason K, Pettersson E: Causes and consequences of proteinuria: The kidney filtration barrier and progressive renal failure. J Intern Med 2003; 254: 216-224.
2. Rostoker G, Ben Maadi A, Remy P, et al: Lowdose angiotensin-converting enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: A prospective study of long-term treatment. Nephrol Dial Transplant 1995; 10: 25-29.
3. Praga M, Borstein B, Andres A, et al: Nephrotic proteinuria without hypoalbuminemia: Clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis 1991; 17: 330-338.
4. Perna A, Schieppati A, Zamora J, et al: Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. Am J Kidney Dis 2004; 44: 385-401.
5. Denton MD, Magee CC, Sayegh MH: Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083-1091.
6. Laskow DA, Vincenti F, Neylan JF, et al: An open-label concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK507 Kidney Transplantation Group. Transplantation 1996; 62: 900-905.
7. Segarra A, Vila J, Pou L, et al: Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or-dependent idiopathic focal glomerulosclerosis: A preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002; 17: 655-662.
8. Mok CC, Tong KH, To CH, et al: Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study. Kidney Int 2005; 68: 813-817.
9. Bao H, Liu ZH, Xie HL, et al: Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008; 19: 2001-2010.
10. Miao LN, Sun J, Yuan H, et al: Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation. Nephrology 2006; 11: 449-454.
11. Praga M, Barrio V, Juarez GF, et al: Tacrolimus mono-therapy in membranous nephropathy: A randomized controlled trial. Kidney Int 2007; 71: 924-930.
12. Ballarin J, Poveda R, Ara J, et al: Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: Results of a pilot study. Nephrol Dial Transplant 2007; 22: 3196-3201.
13. Chen M, Li H, Li XY, et al: Tacrolimus combined with corticosteroids in treatment of nephritic idiopathic membranous nephropathy: A multicenter randomized controlled trial. Am J Med Sci 2010; 339: 233-238.
14. Arikan H, Koc M, Cakalagaoglu F, et al: Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. J Nephrol 2008; 21: 713-721.
15. Cattran DC: Idiopathic membranous glomerulonephritis. Kidney Int 2001; 59: 1983-1994.
16. Isabel R, Shefali V: Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 2010; 25: 1117-1124.
17. Wissmann C, Frey FJ, Ferrari P, et al: Acute cyclosporine induced nephrotoxicity in renal transplant recipients: The role of the transplanted kidney. J Am Soc Nephrol 1996; 7: 267-268.
18. Nankivell BJ, Borrows RJ, Fung CL, et al: Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565.
19. Tse KC, Lam MF, Tang SC, et al: A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 2007; 16: 46-51.
20. Alexopoulos E, Stangou M, Papagianni A, et al: Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000; 15: 1348-1356.
21. Zhang HT, Hu WX, Xie HL, et al: Randomized controlled trial of tacrolimus versus intravenous cyclophosphamide in the induction therapy of class V plus IV lupus nephritis. Chin Nephrol Dial Transplant 2006; 15: 508-514.
22. Roberti I, Vyas S: Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 2010; 25: 1117-1124.